ClinicalTrials.gg
RecruitingNCT07323095Updated Nov 2, 2026

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

A Phase 2 interventional study of ABP-671 plus febuxostat Group 1 and ABP-671 plus febuxostat Group 2 in Chronic Kidney Disease, sponsored by Atom Therapeutics Co., Ltd. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Atom Therapeutics Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 2, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
109th of 164
80 · median 182
Started
2026
with 26 others
Phase 2
22 of 245
5 open now
Primary completion
2027-10
later than 61 of 106 live
Registered
211th of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 109th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 61 of the 106 other live ones, and was the 211th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study
  • Patients who have been diagnosed with CKD based on Clinical Practice Guideline
  • During screening, (BMI) was ≥18.0 and ≤ 40.0 kg/m2
  • The sUA levels > 420 μmol/L (7.0 mg/dL)

Exclusion criteria

Exclusion Criteria:

  • History of renal transplantation
  • The 24-hour urinary protein ≥ 3.5 g/day
  • Liver function abnormality: or alanine aminotransferase, or alkaline phosphatase > 3 times the value (ULN)
  • Subjects with mental disorders who are unable to communicate normally with the investigator
  • Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study
  • The investigator judged that the subject was not suitable for participation in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    ABP-671 plus febuxostat Group 1

    Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice

    Drug: ABP-671 plus febuxostat Group 1

  • Active comparator
    ABP-671 plus febuxostat Group 2

    Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice

    Drug: ABP-671 plus febuxostat Group 2

  • Experimental
    ABP-671 Group

    Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice

    Drug: ABP-671 Group

  • Placebo comparator
    Placebo Group

    Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice

    Drug: Placebo Group

Interventions

  • DrugABP-671 plus febuxostat Group 1

    ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)

  • DrugABP-671 plus febuxostat Group 2

    ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)

  • ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)

  • DrugPlacebo Group

    ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)

06

What researchers measure

Primary outcomes

  1. The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baseline

    Time frame: Week 40

Secondary outcomes

  1. The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baseline

    Time frame: Week 16

  2. Incidence of treatment-emergent adverse events (Safety and Tolerability)

    Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation

    Time frame: Week 40

07

Study locations

2 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Jan 7, 2026
StartActual
Oct 2, 2026was Jun 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
10 sites changed recruiting status (8 now not yet recruiting, 2 now recruiting)
Show 10 sites
  • Renal Research Gosford Pty Ltd · Gosford, Australiano status→Not yet recruiting
  • Genesis Research services · Newcastle, Australiano status→Recruiting
  • Paratus Clinical Research Brisbane · Brisbane, Australiano status→Recruiting
  • Beijing Tsinghua Changgung Hospital · Beijing, Chinano status→Not yet recruiting
  • Peking University First Hospital · Beijing, Chinano status→Not yet recruiting
  • Xuanwu Hospital Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Jiangsu Province Hospital · Nanjing, Chinano status→Not yet recruiting
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
  • Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
  • Zhejiang Provincial People's Hospital · Hangzhou, Chinano status→Not yet recruiting
Nov 2, 2026
Start date
Jun 30, 2026→Oct 2, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    10 sites changed recruiting status (8 now not yet recruiting, 2 now recruiting)
    Show 10 sites
    • Renal Research Gosford Pty Ltd · Gosford, Australiano status→Not yet recruiting
    • Genesis Research services · Newcastle, Australiano status→Recruiting
    • Paratus Clinical Research Brisbane · Brisbane, Australiano status→Recruiting
    • Beijing Tsinghua Changgung Hospital · Beijing, Chinano status→Not yet recruiting
    • Peking University First Hospital · Beijing, Chinano status→Not yet recruiting
    • Xuanwu Hospital Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Jiangsu Province Hospital · Nanjing, Chinano status→Not yet recruiting
    • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
    • Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
    • Zhejiang Provincial People's Hospital · Hangzhou, Chinano status→Not yet recruiting
    Start date Jun 30, 2026→Oct 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07323095
Lead sponsor
Atom Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Oct 2, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Renbo Gao
Contact
renbo.gao@atombp.com
+86 15062305252

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-671

Start the discussion